What Happened

Collate, an AI startup focused on automating life sciences paperwork, raised $95M in funding led by Redpoint Ventures. This brings Collate's total funding to $125M. The company, founded by Surbhi Sarna, has signed over 50 customers since its launch in 2025, including major pharmaceutical and biotech firms.

Who Is Affected

Major life sciences companies, including pharmaceutical firms, medical device manufacturers, and biotech companies, are adopting AI solutions like Collate to streamline regulatory filings and clinical trial documentation.

Market Impact

• Collate's AI tools reduce documentation processing times by 50-90%, addressing a critical bottleneck in bringing new therapies to market.
• The life sciences documentation market is projected to be a significant AI battleground by 2026, similar to the legal sector in 2025.
• Collate's accuracy rates are above 90%, often reaching 97%, with human verification required before document export.

What to Watch

Monitor Collate's growth trajectory as it continues to sign deals with life sciences companies. Also, watch for competitors entering the space as the market for AI-driven documentation solutions expands.